AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
World

UK govt offers reassurance on AstraZeneca vaccine safety

  • Hancock emphasised the serious side effects were "extremely rare", adding that all three of the vaccines so far approved for use in Britain were "safe for all ages".
Published April 8, 2021

LONDON: Britain moved Thursday to reassure the public over the safety of its coronavirus vaccine campaign, after deciding to offer alternatives to an AstraZeneca jab amid blood clot concerns.

Health Secretary Matt Hancock urged people to keep getting inoculated, a day after Britain's medicines regulator said the vaccine developed by the British-Swedish firm was linked to 79 cases of rare clotting and 19 deaths.

But those under 30 are to be offered alternatives the the AstraZeneca vaccine, more than 20 million doses of which have been administered since early December.

Hancock emphasised the serious side effects were "extremely rare", adding that all three of the vaccines so far approved for use in Britain were "safe for all ages".

Addressing those under 30, an age group in which vaccine hesitancy tends to be higher and is largely yet to be offered the jab, he urged young people to keep faith with the UK's vaccine drive.

"The vaccines are safe, and if you want to have the Pfizer vaccine or Moderna vaccine instead then that is fine," Hancock told the BBC, referring to two other vaccines approved by British regulators.

"Covid is a horrible disease and long Covid affects people in their 20s just as much it seems as any other age group and can have debilitating side effects that essentially ruin your life," he added.

The decision Wednesday by the independent Medicines and Healthcare products Regulatory Agency (MHRA), on the advice of the government's Joint Committee on Vaccination and Immunisation (JCVI), has stoked fears the country's successful vaccine programme could be derailed.

Officials said the changes would not impact the rollout timetable of offering a first dose to all adults by the end of July, thanks to supplies from US firm Moderna and Pfizer-BioNTech, a US-German joint effort.

The European Medicines Agency also presented its findings Wednesday on the AstraZeneca jab, saying clotting should be listed as a "very rare" side effect to the vaccine.

Britain, one of the worst-hit countries by the coronavirus pandemic with nearly 127,000 dead, has sped ahead with its vaccination campaign relative to European neighbours.

The UK has administered nearly 32 million first vaccine doses to people -- around 60 percent of the adult population.

Hancock emphasised the impact vaccinations have had on Covid deaths in the UK, saying the number of people dying from Covid was cut in half in the last nine days.

According to modelling by a team at University College London, the country could reach herd immunity from the virus by Monday.

The research, which is yet to be peer reviewed, estimates nearly 75 percent of people should have immunity from the virus by next week.

However, some medical experts urged caution over the assessment.

"Unfortunately, the modelling approach used to produce this analysis has a history of making over-confident and over-optimistic predictions," noted Adam Kucharski, of the London School of Hygiene and Tropical Medicine.

Comments

Comments are closed.